News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tikvah Therapeutics Enters an Exclusive Licensing Agreement With Apkarian Technologies Related to Agents for Treatment of Pain and Pain-Related Indications


7/16/2007 11:59:52 AM

ATLANTA, July 16, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah) and Chicago-based Apkarian Technologies, LLC (Apkarian) announced today that Tikvah has entered into an exclusive licensing agreement with Apkarian for patents and patent applications involving certain agonists of specific sites of the NMDA receptor.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES